about
The feasibility of incorporating Vpx into lentiviral gene therapy vectors.Structural basis for ELL2 and AFF4 activation of HIV-1 proviral transcriptionInhibitors of the Histone Methyltransferases EZH2/1 Induce a Potent Antiviral State and Suppress Infection by Diverse Viral Pathogens.Role of Host Factors on the Regulation of Tat-Mediated HIV-1 Transcription.Dynamics and mechanisms of clonal expansion of HIV-1-infected cells in a humanized mouse modelInstability of 8E5 calibration standard revealed by digital PCR risks inaccurate quantification of HIV DNA in clinical samples by qPCR.Imaging HIV-1 Genomic DNA from Entry through Productive Infection"We Need to Deploy Them Very Thoughtfully and Carefully": Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States-A Qualitative Inquiry.RNA flow cytometric FISH for investigations into HIV immunology, vaccination and cure strategies.Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique.A chalcone derivative reactivates latent HIV-1 transcription through activating P-TEFb and promoting Tat-SEC interaction on viral promoter.Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui.Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.Shock and kill with caution.Control of HIV infection by IFN-α: implications for latency and a cure.Role of HIV-specific CD8(+) T cells in pediatric HIV cure strategies after widespread early viral escape.Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells.T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy.A New Agent in the Strategy to Cure AIDS.New Drugs in the Pipeline for the Treatment of HIV: a Review.Efficacy Analysis of Combinatorial siRNAs against HIV Derived from One Double Hairpin RNA Precursor.Myeloid Cell Interaction with HIV: A Complex Relationship.Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.Optimization and comparison of CD4-targeting lipid-polymer hybrid nanoparticles using different binding ligands.Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment.Tools for Visualizing HIV in Cure Research.NF-κB-Chromatin Interactions Drive Diverse Phenotypes by Modulating Transcriptional Noise.The HIV-1 accessory proteins Nef and Vpu downregulate total and cell surface CD28 in CD4+ T cells.eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients.Bovine single chain Fv antibody inhibits bovine herpesvirus-1 infectivity by targeting viral glycoprotein D.Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs.Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins.The KAT5-Acetyl-Histone4-Brd4 axis silences HIV-1 transcription and promotes viral latency.Comparative Proteomic Profiling and Biomarker Identification of Traditional Chinese Medicine-Based HIV/AIDS Syndromes.Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART.Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation.Short-term pIFN-α2a treatment does not significantly reduce the viral reservoir of SIV-infected, ART-treated rhesus macaques.
P2860
Q37350713-8AF0BCCD-8D0F-4451-A3AE-55A02380A787Q37622516-C29E1DA4-181A-4D88-8501-20007855E903Q38156730-9571915F-A939-442B-BBE3-61C4083024B5Q38430337-F261C092-A8E5-41CB-B767-C3F3F962F75CQ38430518-52D959CE-0B5C-4BCE-A170-3D4C3E95E7D5Q38705900-4C06B993-C287-438D-8FC5-F35B9CFA4E4FQ38714324-81B78AFA-AA24-4B9F-B302-51EE630DF579Q38754318-A109D4C7-2F7C-44DF-B3C9-43FACA018969Q40053205-914EF762-40F3-4959-922C-3814618D46C2Q40054042-976078E9-9482-4D42-BD03-3C3326347EA2Q40054870-7BAAE514-CDFF-42D6-92D9-808C9A0D1A85Q40069617-28981DFA-1D11-4F8F-AAB5-DF24CF59862DQ40069803-C7E22848-F651-4049-9DC9-61D24D96EB5FQ40120304-C3AA34BA-9573-4B92-9BF5-43773BFDEE5EQ40187580-81761685-4773-47E9-AFA2-B20FD0264E59Q40507710-FB4B9D17-0726-4E8D-9790-196265A5983EQ41922021-BCEAE2CE-A0DD-40E2-BE3A-4494D89BECBBQ41923263-4156ECD4-E07F-4280-A348-568DAC59ECD8Q41928841-BA8380FE-DB74-4448-95F5-258A377FA423Q41933638-794CFFFC-C7A7-4E39-8A06-15CE3A3A5EE5Q42859475-D1614043-9994-4A41-B92A-7747199A83FDQ45067800-5C475B7B-BF63-482F-8809-7C95C367C563Q47095469-1EA98D17-B239-4914-A0F1-66C3C742BBAEQ47141408-5828C14A-EDA1-4FB1-BE50-2383A3F24388Q47218587-1554BF25-7C61-487C-8562-A286D4DDFF3FQ47225568-A738CA7F-D663-431B-8FCF-313E156D8B5FQ47307973-E28C9174-D60E-47FB-A38F-D6F5A8DBE6F4Q47548551-AC2B4D62-6B08-42E0-87B2-DA2472AE7F56Q47551768-DCB90FA2-997B-495F-8023-C586B41B53F4Q47554270-86B42F8B-25C2-4D99-9039-E6C83D1E9EE2Q47564080-3EE02DFB-DFBE-4BEE-8AC5-3F7F87BB6C48Q47602852-F1D59A53-1D9A-4518-918B-636430ACD793Q48113493-34D3200B-4B0B-45DB-BAC7-7FE99975CB89Q49925023-454BB7C8-26F5-4119-96B0-9CEFFB6B7C6FQ50022535-7EC200F9-2031-40BC-A206-AD847A91B3D7Q52312695-DD55D802-F5BC-41A0-B676-F6B46E7BA6E4Q52665690-650B2613-03F1-4584-8E0D-7B34D02980BDQ52727145-D6729C02-26E4-453B-B4AD-58F7180E8BFAQ54216878-06A8172F-829B-4B6E-9B83-1151E356185AQ54222562-A2C80905-E49B-4C92-B5F9-D1B1D41BFA59
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Latency reversal and viral clearance to cure HIV-1.
@ast
Latency reversal and viral clearance to cure HIV-1.
@en
type
label
Latency reversal and viral clearance to cure HIV-1.
@ast
Latency reversal and viral clearance to cure HIV-1.
@en
prefLabel
Latency reversal and viral clearance to cure HIV-1.
@ast
Latency reversal and viral clearance to cure HIV-1.
@en
P2093
P2860
P356
P1433
P1476
Latency reversal and viral clearance to cure HIV-1.
@en
P2093
Daria J Hazuda
David M Margolis
J Victor Garcia
P2860
P304
P356
10.1126/SCIENCE.AAF6517
P407
P577
2016-07-01T00:00:00Z